MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Gastrointestinal problemsm(also see autonomic dysfunction)"

  • 2018 International Congress

    Gastrointestinal Symptoms and Enteric Nerve Dysfunction in A53T Mice

    R. McQuade, P. Rajasekhar, S. Diwakarla, R. Constable, D. Poole, J. Berger, D. Finkelstein, J. Furness (Melbourne, Australia)

    Objective: To investigate the relationship between α synucleinopathy-induced enteric neuropathy and gastrointestinal dysfunction in A53T mice. Background: Approximately 80-90% of PD patients suffer from GI…
  • 2018 International Congress

    Gut microbiota geography in Parkinson’s disease in the world

    M. Hirayama, T. Maeda, T. Minato, M. Itoh, J. Takeda, T. Hamaguchi, M. Katsuno, K. Ohno (Nagoya, Japan)

    Objective: The 16 rRNA analysis and the shotgun metagenome analysis in our cohort were compared with 5 previous reports by others. Background: In PD patients,…
  • 2018 International Congress

    Unveiling the function of altered gut microbiota composition in Parkinson’s disease

    A.H. Tan, C.W. Chong, C.S.J. Teh, I.K.S. Yap, M.F. Loke, J. Bowman, S.L. Song, J.Y. Tan, B.H. Ang, Y.Q. Tan, H.S. Yong, A.E. Lang, S. Mahadeva, S.Y. Lim (Kuala Lumpur, Malaysia)

    Objective: To investigate the gut microbiome and metabolome in Parkinson’s disease (PD). Background: Recent evidence revealed that gut microbes promote alpha-synuclein pathology and motor deficits…
  • 2018 International Congress

    GASTROPARK: Multicenter study on the efficacy of dopamine agonists for gastrointestinal symptoms in Parkinson’s disease

    J. Martinez Castrillo, A. Alonso Canovas, G. Fernandez Pajarin, L. Vela Desojo, J. Garcia Caldentey, P. Sanchez Alonso, M. Fernandez Moreno, M. Mata, J. Herreros Rodriguez, J. Infante, J. Ruiz Martinez, C. Ruiz Huete, S. Fanjul Arbos, P. Garcia Ruiz (Madrid, Spain)

    Objective: Main: To assess the modification of gastrointestinal symptoms in patients with Parkinson's disease before and after the introduction of dopamine agonists. Secondary: (1) To…
  • 2018 International Congress

    Clinical characteristics of turkish patients with Parkinson’s disease: A retrospective analysis of 428 patients

    B. Gonenli Kocer, E. Ozturk, S. Comoglu (Ankara, Turkey)

    Objective: To evaluate the demographic, motor and non-motor clinical characteristics of Turkish Parkinson’s disease (PD) patients in our Movement Disorders Outpatient Clinic. Background: Although PD…
  • 2018 International Congress

    Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion

    B. Fernández-Rodríguez, J. Dupouy, E. Harroch, MH. Fabre-Delcros, C. Barthélémy, P. Loubière, K. Barange, C. Brefel-Courbon, O. Rascol, F. Ory-Magne (Toulouse, France)

    Objective: To compare weight variations between three cohorts of patients with advanced Parkinson’s disease (PD): patients during their first year of treatment either with levodopa-carbidopa…
  • 2018 International Congress

    Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection

    S. Isaacson (Boca Raton, FL, USA)

    Objective: We evaluated a subset of patients who were enrolled in the AMIMPAKT trial of sc apomorphine injection to treat morning akinesia (see reference) who…
  • 2018 International Congress

    Non-Motor Symptom In Young Onset Parkinson Disease as a Cause of Pharmacoresistence In Epilepsy

    M. Awadh (Birmingham, United Kingdom)

    Objective: To report an interesting initial presentation of PD causing refractory epilepsy. Background: A lady with refractory depression, presented with first seizure at age 42,…
  • 2018 International Congress

    Characterization of the gastrointestinal dysfunction in mice overexpressing the human mutation (A53T) of alpha-synuclein

    S. Diwakarla, R. Constable, O. Artaiz, D. Finklestein, J. Berger, J. Furness (Melbourne, Australia)

    Objective: The aim of this study was to determine if mice overexpressing the human mutation of alpha-synuclein develop gastrointestinal (GI) dysfunction, and to understand the…
  • 2018 International Congress

    Evaluation of the Effect of STN-DBS on the Gastrointestinal Symptoms in Patients with Parkinson’s Disease via GIQLI

    A. Yilmaz, E. Okuyucu, M. Ugur (Hatay, Turkey)

    Objective: Our aim is to evaluate the effects of Subthalamic Nucleus (STN)-DBS on the quality of life in PD patients by using the Gastrointestinal Quality…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25676 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Effect of marijuana on Essential Tremor: A case report
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley